Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Greencovery B V operates in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This prosecution activity is handled by 1 distinct examiner. The company's current filings are located within 1 distinct art unit, which indicates the technical scope of the applications. This structure shows that the company's active cases are not spread across multiple examiners or units at the USPTO.
CARR, DEBORAH D is the busiest examiner for this portfolio and is responsible for 1 pending office action. Since the total number of pending office actions is 1, this examiner manages the active matters for the company. The 1 distinct art unit involved in the prosecution suggests that the subject matter is specialized. Practitioners should note that the 1 distinct examiner has a significant role in the company's immediate patent strategy.
The involvement of CARR, DEBORAH D in 1 distinct art unit means that the prosecution experience is centralized. Having 1 pending office action allows for a dedicated focus on the requirements of the assigned examiner. The data indicates that the company's Biotechnology & Pharmaceuticals portfolio is currently managed through a single point of contact at the USPTO, which simplifies the administrative tracking of the 1 busiest examiner pending workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CARR, DEBORAH D | 1 | 81.8% | +2.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264008 | ACID RECOVERY | CARR, DEBORAH D | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264008 | ACID RECOVERY | CARR, DEBORAH D | 1691 | §103§112 | Non-Final OA | — | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGreencovery B V has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Deborah D Carr has the most, with 1 of Greencovery B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
